Lipocine Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
LPCN$1.59-7.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Operations and Comprehensive Income (Loss)
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Revenues: | |||
| License and royalty revenue | $11,198,144 | $109,987 | |
| Minimum guaranteed royalties revenue (reversal of variable consideration) | - | (2,960,805) | |
| Total revenues (reversal of variable consideration), net | 11,198,144 | (2,850,818) | |
| Operating expenses: | |||
| Research and development | 7,351,753 | 10,175,251 | |
| General and administrative | 5,001,426 | 4,904,888 | |
| Total operating expenses | 12,353,179 | 15,080,139 | |
| Operating loss | (1,155,035) | (17,930,957) | |
| Other income: | |||
| Interest and investment income | 1,146,902 | 1,366,940 | |
| Unrealized gain on warrant liability | 17,166 | 212,690 | |
| Total other income | 1,164,068 | 1,579,630 | |
| Income (loss) before income tax expense | 9,033 | (16,351,327) | |
| Income tax expense | (681) | (755) | |
| Net income (loss) | 8,352 | (16,352,082) | |
| Issuance of Series B preferred stock dividend | - | (89) | |
| Net gain (loss) attributable to common shareholders | $8,352 | $(16,352,171) | |
| Basic income (loss) per share attributable to common stock | $ | - | $(3.10) |
| Weighted average common shares outstanding, basic | 5,338,957 | 5,269,671 | |
| Diluted income (loss) per share attributable to common stock | $ | - | $(3.14) |
| Weighted average common shares outstanding, diluted | 5,422,604 | 5,269,671 | |
| Comprehensive income (loss): | |||
| Net income (loss) | $8,352 | $(16,352,082) | |
| Net unrealized gain on available-for-sale securities | 1,879 | 27,580 | |
| Comprehensive gain (loss) | $10,231 | $(16,324,502) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.